Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

VK2735 cycle length: what human studies ran

InvestigationalAHuman trial evidence
Short answer: there is no established VK2735 cycle length or break. The human studies below ran for set periods under monitoring; none tested repeated courses.

Treatment and follow-up in human studies

  1. VENTURE: 13 weeks of treatment 1. VANQUISH 1 and 2: primary endpoint at week 78 5,6. Oral phase 2: 13 weeks 4. SUNRISE 1 and 2: 68 weeks 7,8.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • VK2735 combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established VK2735 cycle length?
No. Human studies administered VK2735 for the periods listed on this page. Those are study durations; none tested an on-and-off schedule or a break.
What is the longest human study of VK2735?
The durations are listed on this page with their sources; compare them directly rather than relying on a summary.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
VK2735 dosing reference Full research page

References

  1. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity (Silver Spring). 2026
  2. VK2735 for Weight Management Phase 2 (VENTURE, NCT06068946), registry record ClinicalTrials.gov. 2023
  3. Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 (NCT05203237), registry record ClinicalTrials.gov. 2021
  4. VK2735 for Weight Management Phase 2 (VENTURE Oral Dosing, NCT06828055), registry record ClinicalTrials.gov. 2024
  5. VK2735 for Weight Management Phase 3 (VANQUISH 1, NCT07104500), registry record ClinicalTrials.gov. 2025
  6. VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2, NCT07104383), registry record ClinicalTrials.gov. 2025
  7. Oral VK2735 for Weight Management Phase 3 (SUNRISE 1, NCT07868835), registry record ClinicalTrials.gov. 2026
  8. Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2, NCT07868939), registry record ClinicalTrials.gov. 2026
  9. Drugs@FDA application data queried through openFDA for VK2735 (no matching application record returned on 22 October 2026) openFDA / Drugs@FDA. 2026
  10. World Anti-Doping Agency International Standard Prohibited List 2026 WADA. 2026
  11. PubChem compound name search for VK2735 (no compound record returned on 22 October 2026) PubChem. 2026